Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and iCDE with Virotherapy for Primary Effusion Lymphoma
NCT00217503Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and bortezomib in primary effusion lymphoma (PEL), sponsored by National Cancer Institute. Primary endpoint: Complete Response Rate. Started Jul 2005; status: completed.
02
Drugs
bevacizumabbortezomib
03
Conditions
primary effusion lymphoma (PEL)
Beyond the preview
Go deeper on NCT00217503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217503.